Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2026)
Catalyst Pharmaceuticals (CPRX) reported EBT Margin of 56.38% for Q1 2026, up 598.0% on a YoY basis from 8.08% in Q1 2025, and up 19.67% quarter-over-quarter from 47.11% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals has reported EBT Margin for 9 years, with the latest figure at 56.38% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 598.0% year-over-year to 56.38%; the trailing twelve-month figure through Mar 2026 stood at 49.66% (up 132.0% YoY), and the FY2025 full-year result was 48.14%, up 416.0% from the prior year.
- EBT Margin for Q1 2026 stood at 56.38%, up from 47.11% in the prior quarter.
- The five-year high for EBT Margin was 56.38% in Q1 2026, with the low at 37.03% in Q3 2023.
- Historically, EBT Margin has averaged 41.88% across 5 years, with a median of 47.11% in 2025.
- Annual changes were most pronounced in 2023 — EBT Margin sank 8246 bps — and 2024, when it soared 8148 bps.
- Catalyst Pharmaceuticals' EBT Margin stood at 54.33% in 2022, then retreated by 22 bps to 42.24% in 2023, then climbed by 24 bps to 52.31% in 2024, then declined by 10 bps to 47.11% in 2025, then rose by 20 bps to 56.38% in 2026.
- The last three EBT Margin figures came in at 56.38% (Q1 2026), 47.11% (Q4 2025), and 47.87% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Catalyst Pharmaceuticals | 3.84 Bn | 3.08 Bn | 134.92 Mn | 56.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.38% |
| Dec 31, 2025 | 47.11% |
| Sep 30, 2025 | 47.87% |
| Jun 30, 2025 | 47.28% |
| Mar 31, 2025 | 50.41% |
| Dec 31, 2024 | 52.31% |
| Sep 30, 2024 | 44.45% |
| Jun 30, 2024 | 45.46% |
| Mar 31, 2024 | 29.53% |
| Dec 31, 2023 | 42.24% |
| Sep 30, 2023 | -37.03% |
| Jun 30, 2023 | 48.72% |
| Mar 31, 2023 | 43.71% |
| Dec 31, 2022 | 54.33% |
| Sep 30, 2022 | 45.43% |
| Jun 30, 2022 | 53.18% |
| Mar 31, 2022 | 40.52% |
| Dec 31, 2021 | 33.45% |
| Sep 30, 2021 | 39.14% |
| Jun 30, 2021 | 43.72% |